Evidence map›Paper›PMID 27737495›Full record

ReviewAnnals of the New York Academy of Sciences2016

A countermeasure development pipeline.

Calum A MacRae, Gerry Boss, Matthew Brenner, Robert E Gerszten, Sari Mahon, Randall T Peterson

Abstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Calum A MacRaeBrigham and Women's Hospital, Boston, Massachusetts. camacrae@bics.bwh.harvard.edu.
Gerry BossDepartment of Medicine, University of California, San Diego, San Diego, California.
Matthew BrennerUniversity of California, Irvine, Irvine, California.
Robert E GersztenHarvard Medical School, Boston, Massachusetts.
Sari MahonDepartment of Medicine, University of California, San Diego, San Diego, California.
Randall T PetersonHarvard Medical School, Boston, Massachusetts.

Funding

Validating promising drug candidates in mammalian models of CN poisoningU54NS079201 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI PETERSON, RANDALL T, PETERSON, RAYMOND J · 2012 to 2016
$12.6M
Unbiased screens in zebrafish for new classes of cyanide countermeasureU01NS063563 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI MACRAE, CALUM A. · 2008 to 2011
$1.1M
NINDS NIH HHS U01 NS063563NINDS NIH HHS U54 NS079201
6 · The paper itself

Abstract

We have developed an integrated pipeline for countermeasure discovery that, under the auspices of the National Institutes of Health Countermeasures Against Chemical Threats network, is one of the few efforts within academia that by design spans the spectrum from discovery to phase I. The successful implementation of this approach for cyanide would enable efficient proof-of-concept studies that would lay the foundation for a generalizable strategy for parallel mechanistic studies and accelerated countermeasure development in the face of new and emerging chemical threats.

Indexed as

Program DevelopmentAnimalsBiomedical ResearchCyanidesDrug DiscoveryHumansMetabolomicsNational Institutes of Health (U.S.)United StatesCyanidesanimal modelscountermeasurecyanidedrug discoverymetabolomics

Identifiers

PMID27737495
PMCPMC6420827

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.